Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer

To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients.   Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 201...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2019-05, Vol.15 (14), p.1617-1627
Main Authors: Han, Guangjie, Shi, Jianfei, Mi, Lili, Li, Ning, Shi, Huacun, Li, Cuizhen, Shan, Baoen, Yin, Fei
Format: Article
Language:English
Subjects:
advanced gastric cancer
adverse reactions
Cancer therapies
Cell division
Chemotherapy
Committees
Gastric cancer
Lymphocytes
Medical prognosis
Neutrophils
NLR
paclitaxel liposomes
Patients
prognosis
SOX
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients.   Stage IIb–IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010–2013, and followed up until 2015 or death. Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I–II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor.   First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2018-0439